M&A

News

BMS wagers $14bn on Karuna’s schizophrenia drug

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim

News

Illumina admits defeat in Grail quest, opting to divest

Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair.

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

News

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos

News

Medtronic drops $738m takeover of wearable insulin pump firm

Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple b

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

BMS wagers $14bn on Karuna’s schizophrenia drug

Illumina admits defeat in Grail quest, opting to divest

Final obstacles in front of Pfizer, Seagen merger fall

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Medtronic drops $738m takeover of wearable insulin pump firm

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

Amgen's Horizon buyout delivers Sjögren's disease win

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks